NCT03276962已完成2 期
Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or With-out Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 1,500
- 试验地点
- 3
- 主要终点
- Incidence of Clinical Malaria Meeting the Primary Case Definition
研究概览
简要总结
The study intends to establish proof of concept for a fractional dose schedule under conditions of natural exposure in children 5-17 months old at first vaccination. The study also aims to establish the role of third dose spacing in a fractional dose schedule, describe the effect of an earlier full fourth dose at Month 14 and describe the effect of multiple fractional or full yearly doses.
详细描述
The current study intends to establish proof of concept (POC) for a fractional dose schedule under conditions of natural exposure. The study will be conducted in children 5-17 months old at first vaccination living in areas of mid to high malaria transmission, in line with the age group recommended by the World Health Organization (WHO) for the implementation of the RTS,S/AS01E vaccine. Results from this study will be critical in informing future possibilities for the development of vaccine-based strategies which, in combination with other interventions, may contribute to the malaria elimination agenda.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 5 Months 至 17 Months（Child）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Participants' parent(s)/LAR(s) who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g. return for follow-up visits).
- •Signed or thumb-printed and witnessed informed consent obtained from the parent(s)/LAR(s) of the participant prior to performance of any study specific procedure. Where parent(s)/LAR(s) are illiterate, the consent form will be countersigned by an independent witness.
- •A male or female between, and including, five and 17 months of age at the time of the first vaccination.
- •Healthy participants as established by medical history and clinical examination before entering into the study.
- •Previously received three documented doses of diphtheria, tetanus, pertussis, hepatitis B vaccine (DTPHepB), and at least three doses of oral polio vaccine.
排除标准
- •Child in care.
- •Use of a drug or vaccine that is not approved for that indication (by one of the following regulatory authorities: Food and Drug Administration [FDA; USA] or European Union member state or WHO [with respect to prequalification]) other than the study vaccines during the period starting 30 days before the first dose of study vaccines (Day -29 to Day 0), or planned use during the study period.
- •Any medical condition that in the judgment of the investigator would make intramuscular injection unsafe.
- •Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drugs during the period starting six months prior to the first vaccine dose. For corticosteroids, this will mean prednisone (0.5 mg/kg/day (for pediatric participants) or equivalent. Inhaled and topical steroids are allowed.
- •Planned administration/administration of a vaccine not foreseen by the study protocol in the period starting seven days before each dose and ending seven days after each dose of vaccine administration.
- •Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational vaccine/product (pharmaceutical product or device).
- •Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required).
- •Family history of congenital or hereditary immunodeficiency.
- •History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccines.
- •History of anaphylaxis post-vaccination.
- •History of any, or documented, serious adverse reaction to rabies vaccination.
- •Contraindication to rabies vaccination (Rabipur is contraindicated in participants with history of a severe hypersensitivity to any of the ingredients in the vaccine. Note that the vaccine contains polygeline and residues of chicken proteins, and may contain traces of neomycin, chlortetracycline and amphotericin B).
- •Major congenital defects.
- •Serious chronic illness.
- •Children with a past history of a neurological disorder or atypical febrile seizure (a febrile seizure is atypical if it meets one of the following criteria: not associated with fever; lasts > 5 minutes; focal (not generalized); followed by transient or persistent neurological abnormality; occurs in a child < 6 months of age).
- •Acute disease and/or fever at the time of enrolment. Fever is defined as temperature ≥ 37.5°C/99.5°F for oral, axillary or tympanic route, or ≥ 38.0°C/100.4°F for rectal route.
- •Participants with a minor illness (such as mild diarrhea, mild upper respiratory infection) without fever may, be enrolled at the discretion of the investigator.
- •Administration of immunoglobulins and/or any blood products during the period starting three months before the first dose of study vaccine or planned administration during the study period.
- •Moderate or severe malnutrition at screening defined as weight for age or weight for height Z-score < -
- •Hemoglobin concentration < 8 g/dl at screening.
- •Same sex twins (to avoid misidentification).
- •Maternal death.
- •Prior receipt of an investigational malaria vaccine.
结局指标
主要结局
Incidence of Clinical Malaria Meeting the Primary Case Definition
时间窗: From Month 2.5 to Month 14
The primary case definition is: Plasmodium (P.) falciparum asexual parasitemia greater than (\>)5000 parasites/microliters (μl) and presence of fever (axillary temperature greater than or equal to \[≥\]37.5°C) at the time of presentation and occurring in a child who is unwell and brought for treatment to a healthcare facility. The incidence is expressed as a person year rate for each group (n/T), representing the number of events (n) reported over the risk period, which was counted in days and expressed as person years at risk (T). The objective of this endpoint was to demonstrate the superiority of a Fx012-14-mFxD Group compared to a standard schedule of RTS,S/AS01E with three full doses (R012-20+R012-14 Group) in terms of vaccine efficacy. This analysis was reported for the R012-20+R012-14 Group (Pooled group) because the interventional strategy (1st dose at Month 0, 2nd dose at Month 1, 3rd dose at Month 2) was the same for both the R012-20 group and the R012-14 group until Month 14.
次要结局
- Number of Seropositive Participants for Anti-hepatitis B (Anti-HB) Antibodies(Before Dose 1, one month post-Dose 2, before and one month post-Dose 3, before and one month after Dose 4, before and one month after each yearly dose and at Study End (Month 50))
- Number of Participants With Generalized Convulsive Seizures(During the 7-day (Day 0 to Day 6) follow-up period after any dose of study vaccine)
- Incidence of Clinical Malaria Meeting the Primary and Secondary Case Definitions of the Fx012-14-mFxD Group Versus the R012-20 Group(From Month 0 to Month 50)
- The Prevalence of P. Falciparum Infections Defined by Positive Blood Slide at Each Cross-sectional Survey(Monthly from Month 0 to Month 20 and every 3 months thereafter until Study End (Month 50))
- Number of Participants With Any Adverse Events (AEs) and SAEs Leading to Withdrawal From Further Vaccination(From Day 0 to Month 50)
- Incidence of Clinical Malaria Meeting the Primary and Secondary Case Definitions of the Fx012-14-mFxD Group Versus the R012-14-mD Group(From Month 0 to Month 50)
- Incidence of P. Falciparum Infections Defined by Positive Blood Slide(Month 0 to Month 14)
- Number of Seropositive Participants for Anti-circumsporozoite (Anti-CS) Antibodies(Before Dose 1, one month post-Dose 2, before and one month post-Dose 3, before and one month after Dose 4, before and one month after each yearly dose and at Study End (Month 50))
- Antibody Concentrations for Anti-HB(Before Dose 1, one month post-Dose 2, before and one month post-Dose 3, before and one month after Dose 4, before and one month after each yearly dose and at Study End (Month 50))
- Antibody Concentrations for Anti-CS(Before Dose 1, one month post-Dose 2, before and one month post-Dose 3, before and one month after Dose 4, before and one month after each yearly dose and at Study End (Month 50))
- Number of Participants With Any, Fatal and Related Serious Adverse Events (SAEs)(From Day 0 to Month 50)
- Number of Participants With Cerebral Malaria and Severe Malaria(From Day 0 to Month 50)
- Number of Participants With Any Solicited Local Symptoms(During the 4-day (Day 0 to Day 3) follow-up period after Dose 3, Dose 4, Dose 5 and Dose 6 of study vaccination)
- Number of Participants With Potential Immune Mediated Diseases (pIMDs)(From Day 0 to Month 50)
- Number of Participants With Meningitis(From Day 0 to Month 50)
- Number of Participants With Seizures(During the 30-day (Day 0 to Day 29) follow-up period after any dose of study vaccine)
- Number of Participants With Any Unsolicited AEs(During the 30-day (Day 0 to Day 29) follow-up period following the 1st 3 doses and post dose 4, 5 and 6 of study vaccine)
- Number of Participants With Grade 4 Hematology and Biochemical Toxicities at 30 Days Post-Dose 3(At 30 days post-Dose 3)
- Number of Participants With Any Solicited General Symptoms(During the 4-day (Day 0 to Day 3) follow-up period after Dose 3, Dose 4, Dose 5 and Dose 6 of study vaccination)
- Number of Participants With Grade 4 Hematology and Biochemical Toxicities at 7 Days Post-Dose 3(At 7 days post-Dose 3)
- Number of Participants With Grade 4 Hematology and Biochemical Toxicities Before Dose 3(Before Dose 3 (at Month 2))
研究者
研究点 (3)
Loading locations...
相似试验
已完成
2 期
Efficacy, Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Evaluating Different Dose Schedules in a Sporozoite Challenge Model in Healthy Malaria-naïve AdultsMalariaNCT03162614GlaxoSmithKline154
已完成
2 期
Safety and Immunogenicity Study of GSK Biologicals Tuberculosis Vaccines (692342) to Healthy AdultsTuberculosisNCT00621322GlaxoSmithKline180
已完成
3 期
A Study to Compare the Immunogenicity of GSK Biologicals' 10Pn-PD-DiT 4-dose Presentation to the Licensed 1-dose Synflorix™ (10Pn-PD-DiT) Vaccine When Co-administered With DTPw-combination Vaccine in Healthy InfantsInfections, StreptococcalNCT02447432GlaxoSmithKline320
已完成
2 期
Safety and Immune Response Study of an Investigational Pneumococcal Vaccine.Prophylactic Pneumococcal DiseasesNCT00327522GlaxoSmithKline10
已完成
3 期
Safety and Immunogenicity Study of GSK Biologicals' Seasonal Influenza Candidate Vaccine (GSK2321138A)InfluenzaNCT01204671GlaxoSmithKline4,659